Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma

Figure 1

Graph depicting various white cell lines following initiation of immunotherapy (nivolumab) in November 2015.